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Summary  The  current  trend  is  to  reserve  the  diagnosis  of  premature  ejaculation  (PE)  for
cases where  penetration  lasts  for  about  one  minute  or  less.  The  rationale  is  that  the  aetiol-
ogy is  primarily  bio-constitutional,  and  that  long-term  pharmacological  treatment  is  the  only
viable option.  However,  the  literature  contains  little  scientiﬁc  evidence  to  support  this  argu-
ment. In  fact,  a  good  number  of  individuals  who  suffer  from  overly  rapid  ejaculation  present
with penetration  duration  exceeding  one  minute,  and  even  severe  forms  of  PE  have  responded
favourably  to  psycho-sexological  treatment.  Moreover,  although  certain  biological  variables  are
known to  inﬂuence  ejaculation  latency  time,  nothing  indicates  that  they  play  an  exclusive  role
of psychosocial  etiological  factors  in  severe  PE.  Therefore,  it  would  be  ‘premature’  to  base  a
PE diagnosis  on  a  maximum  penetration  duration  of  one  minute,  which  should  instead  be  con-
sidered a  severity  gradient.  Given  that  desired  criteria  for  penetration  duration  often  exceed
biological  norms,  it  would  be  inappropriate  to  propose  that  only  the  most  severe  forms  of  PE
have constitutional  origins.  In  any  case,  the  constitution  is  relatively  ﬂexible,  and  can  respond
to adaptive  learning.  An  adaptive  learning  approach  would  undoubtedly  be  more  difﬁcult  to
apply in  severe  cases,  but  not  impossible.  The  issue  of  whether  to  use  pharmacological  versus
psycho-sexological  treatment  could  be  sidestepped  by  moving  beyond  the  single  criterion  of
ejaculation  latency.
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Qualifying ejaculation ‘prematurity’: two
opposing viewpoints
Everybody,  or  almost  everybody,  agrees  that  premature
ejaculation  (PE)  may  be  considered  a  sexual  dysfunction  if
three  criteria  are  met:  ejaculation:
•  occurs  rapidly;
•  is  felt  to  be  outside  the  man’s  control;
•  generates  a  feeling  of  distress,  or  at  least  dissatisfaction.
Beyond  this  common  ground,  however,  conceptions
diverge,  mainly  concerning  the  criterion  of  rapidness
(Bonierbale,  2013;  Kempeneers  et  al.,  in  press).
In  schematic  terms,  there  are  two  main  opposing  view-
points:
•  on  the  one  hand,  there  is  what  is  known  as  the
‘‘subjectivist’’  view.  In  its  most  extreme  form,  this  view
proposes  the  individual’s  wishes,  or  subjectivity,  as  the
only  relevant  referent:  an  ejaculation  is  considered  pre-
mature  when  it  regularly  occurs  before  the  man  wants  it
to,  and  that  is  all.  Rapidness  is  therefore  reduced  to  lack
of  control.  This  viewpoint  is  well  expressed  in  works  by  De
Carufel  (2009)  and  Metz  and  McCarthy  (2003), among  oth-
ers.  In  this  sense,  PE  would  affect  approximately  15  to  30  %
of  the  male  population  (Laumann  et  al.,  2005;  Levinson,
2008;  Park  et  al.,  2010;  Porst  et  al.,  2007);
•  on  the  other  hand,  there  is  the  ‘‘objectivist’’  view,  which
seeks  to  objectively  determine  ejaculation  rapidness  in
terms  of  regular  occurrence  at  below  a  maximum  pene-
tration  duration.  Various  authors  have  proposed  various
benchmarks,  ranging  from  15  seconds  (WHO,  1994) to
seven  minutes  (Schover  et  al.,  1982).  Currently,  the  trend
is  to  retain  a  one-minute  maximum  threshold.  In  this
sense,  less  than  5  %  of  the  population  would  be  affected
(APA,  2013;  Jannini  et  al.,  2013;  McMahon  et  al.,  2008).
Intrinsic  to  these  two  schools  of  thought  are  opposing
ideal  types  of  normality:
•  a  purely  subjectivist  approach  would  be  to  regard  as
normal  a  man’s  total  voluntary  control  over  his  own  ejac-
ulation.  Pushed  to  the  extreme,  this  conception  becomes
a  kind  of  biological  utopia;
•  a  purely  objectivist  approach  would  be  to  judge  normal-
ity  based  on  statistics  alone,  with  the  potentially  harmful
effect  of  delegitimising  the  notion  of  ‘‘disorder,’’  and
consequently  the  therapeutic  intention,  beyond  the  piv-
otal  value.
Ejaculation and its timing: observational data
The  general  population
The  ﬁrst  investigation  to  use  objective  measures  of  pene-
tration  time  in  the  general  population  was  conducted  by
Waldinger  et  al.  (2005)  in  several  national  samples.  The
median  duration  of  coitus  was  5.4  minutes,  with  differences
across  countries  ranging  from  3.7  minutes  in  Turkey  to  7.6  in
the  United  Kingdom.  A  second  investigation  by  Waldinger
et  al.  (2009)  reported  similar  results:  4.4  minutes  in  Turkey,
10  in  the  United  Kingdom,  and  six  for  the  total  sample.
Individual  desires
In  comparison  to  the  ﬁndings  of  Waldinger  et  al.,  a  survey
conducted  by  Montorsi  (2005)  revealed  that  the  respon-
dents  estimated  normal  penetration  duration  at  13  minutes
on  average  for  Americans  and  9.6  for  Europeans.  Else-
where,  Corty  and  Guardiani  (2008)  surveyed  34  experienced
American  and  Canadian  sexologists  and  found  that  what
was  deemed  ‘‘desirable’’  duration,  that  is,  from  seven
to  13  minutes  of  penetration,  exceeded  the  statistical
norm  of  three  to  seven  minutes,  which  was  considered
‘‘adequate’’  duration.  This  is  probably  not  unconnected
to  the  widespread  opinion  that  achieving  an  orgasm
requires  longer  tactile  stimulation  for  women  than  for  men:
ﬁve  to  15  minutes  on  average  for  women  versus  four  to
seven  minutes  for  men  (Nagoski,  2010).  In  short,  when  it
comes  to  penetration  duration,  the  reference  standards
clearly  exceed  the  statistical  standards.  What  could  —  at
least  in  the  Western  world  —  be  considered  a  biological  norm
appears  to  be  rather  unsatisfactory  from  both  a  hedonic  and
a  sociocultural  perspective.  There  is  no  shortage  of  men  who
would  like  to  delay  their  ejaculation  longer  than  usual,  just
as  they  would  like  to  be  a  little  taller  and  smarter  than  the
average.  Leaving  aside  the  distress  stemming  from  overly
rapid  ejaculation  would  being  too  short  or  not  smart  enough
count  as  a  ‘disorder’?  This  is  not  just  a  biological  issue;  it
is  also  psychological,  sociocultural,  and  relational  (Giami,
2013).  Thus,  whereas  ejaculation  can  often  be  delayed  by
means  of  chemical  or  behavioural  therapy,  psychosexologi-
cal  counselling  can  provide  additional  help  through  training
in  how  to  deal  with  the  limitations  of  one’s  condition.  This
summarizes  the  available  treatment  options.
PE  in  men
In  a  stop-watch  study  in  a  sample  of  110  men  who  con-
sulted  for  PE  dysfunction,  Waldinger  et  al.  (1998)  observed
that  90  %  of  individuals  presented  a  primary  (lifelong)  and
generalised  form  involving  ejaculation  within  one  minute
of  penetration,  with  99  %  within  two  minutes.  A  regularly
cited  study  by  McMahon  (2002)  in  over  1000  Australian  men
treated  for  PE  produced  similar  results.  However,  as  this
study  is  included  in  the  scientiﬁc  database  in  the  form  of  an
abstract  for  a  conference  poster  presentation,  the  method-
ological  details  remain  unknown.
In the  wake  of  these  two  studies,  a  group  of  experts  from
the  International  Society  for  Sexual  Medicine  (ISSM)  pro-
posed  reserving  the  primary  and  generalised  PE  diagnosis
for  individuals  presenting  ejaculation  latency  of  about  one
minute  or  less  (McMahon  et  al.,  2008).  Voices  were  raised  to
persuade  the  American  Psychiatric  Association  (APA),  author
of  the  seminal  Diagnostic  and  Statistical  Manual  of  Mental
disorders,  to  integrate  this  ceiling  value  into  their  manual
(Segraves,  2010).  They  were  evidently  convinced,  because
the  DSM-5,  published  in  May  2013,  now  makes  this  distinction
(APA,  2013).
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Apart  from  McMahon’s  study,  for  which  only  the  abstract
is  available,  the  study  by  Waldinger  et  al.  (1998),  based  on
a  one-minute  pivotal  value,  provides  little  solid  corrobo-
ration.  Some  studies  even  found  contradictory  results,  for
instance,  two  stop-watch  studies,  one  in  the  United  States
(Patrick  et  al.,  2005),  the  other  in  Europe  (Giuliano  et  al.,
2008),  each  investigating  200  men  diagnosed  with  PE.  It
appeared  that  over  40  %  of  ejaculations,  although  reported
as  premature,  actually  occurred  two  minutes  after  pene-
tration.  Nevertheless,  it  is  notable  that,  unlike  the  study
by  Waldinger  et  al.,  these  two  studies  did  not  exclusively
address  primary  and  generalised  forms  of  PE.
If  we  can  agree  with  Althof  et  al.  (1995),  Pryor  et  al.
(2006),  and  Rosen  et  al.  (2007)  that  the  self-estimates
reported  by  men  suffering  from  PE  reﬂect  actual  penetration
duration,  we  must  also  cite  two  recent  studies  that  contra-
dict  the  observations  of  Waldinger  et  al.  One  investigation
by  McMahon  et  al.  (2012)  in  the  Asia-Paciﬁc  region  showed
that,  of  816  men  diagnosed  with  PE  based  on  the  prema-
ture  ejaculation  diagnostic  tool  (Symonds  et  al.,  2007),  74  %
reported  ejaculation  latencies  exceeding  two  minutes,  and
almost  90  %  reported  latencies  exceeding  one  minute.  In  a
study  conducted  in  Belgium  by  Kempeneers  et  al.  (2013),
26  %  of  341  subjects  with  primary  and  generalised  PE  diag-
nosis  (DSM-IV-TR  criteria)  reported  penetration  durations
exceeding  two  minutes,  and  about  50  %  reported  durations
exceeding  one  minute.
Determination of the problem and the
treatment
In  the  domains  of  mind  and  behaviour,  the  concepts  of
‘health’  and  ‘disorder’  are  deﬁned  as  much  in  social  as  bio-
logical  terms,  and  the  rationale  for  a  treatment  is  intimately
related  to  the  conception  of  the  problem.
When  adequate  training  and  proper  sexual  education
are  offered  as  ‘treatments’  to  individuals  with  complaints
of  rapid  ejaculation  —  an  estimated  15  to  30  %  of  the  pop-
ulation  —  this  does  not  pose  ethical  problems.  Economic
problems,  maybe,  but  not  so  much  ethical,  and  less  ethi-
cally  disturbing  than  if,  for  example,  training  and  remedial
courses  were  offered  to  individuals  suffering  from  not  feel-
ing  as  intelligent  as  they  would  like.  Although  there  remains
the  larger  issue  of  the  legitimacy  of  social  normalisation,
these  types  of  ‘soft’  treatments  are  perceived  as  not  really
liable  to  harm  the  beneﬁciaries.  Thus,  they  provide  a  reason-
ably  good  ﬁt  with  a  broad  conception  of  a  ‘problem’  that  a
good  number  of  individuals  experience,  a  conception  based
essentially  on  individual  suffering.
It  is  quite  another  story  when  we  consider  pharmacologi-
cal  treatments  and  their  trail  of  medium-  and  long-term  side
effects.  Here,  behavioural  and  mental  normalisation  can
entail  biological  costs  for  individual  users,  costs  that  must
be  weighed  against  the  expected  beneﬁts.  Today  we  hear
regular  denouncements  of  the  large-scale  use  of  psychotrop-
ics  —  which  include  active  agents  used  to  treat  PE  —  due
to  the  associated  biological  costs,  which  represent  a  heavy
price  to  pay  for  the  ‘‘cult  of  performance’’  (Ehrenberg,
1998;  Frances,  2013).  It  would  therefore  appear  preferable
to  limit  these  treatments,  and  consequently  the  diagnosis,
to  cases  that  are  untreatable  by  the  ‘softer’  methods.  In
this  perspective,  a  potentially  toxic  treatment  should  target
only  the  part  of  the  problem  —  the  ‘real’  problem  —  that  is
attributable  to  a  biological  abnormality,  to  the  exclusion  of
problems  with  psychosocial  causes.  Accordingly,  the  recog-
nition  of  an  essentially  biological  problem  would  indicate
the  therapeutic  use  of  doping  agents.
Should primary severe PE be considered a
neurobiological disorder? Why? How? With
what limitations?
How  did  the  ISSM  and  the  APA  end  up  determining  a  maximum
threshold  of  one  minute  of  penetration  as  the  diagnostic
criterion  for  PE,  based  on  such  paltry  scientiﬁc  evidence?
It  is  hard  not  to  hypothesise  that  this  consistent  view  was
adopted  in  order  to  justify  a  pharmaceutical  approach  to
the  problem.
From  a  pharmaceutical  industry  perspective,  the  estab-
lishment  of  a  ceiling  duration  would  certainly  have  the
disadvantage  of  delegitimising  therapeutic  intervention
beyond  the  pivotal  value  (Waldinger,  2008),  but  it  would
also  have  the  advantage  of  justifying  pharmaceutical  inter-
vention  within  this  limitation,  and  even  more  so  if  the  form
of  PE  is  deﬁned  as  a  biological  abnormality,  and  if  phar-
macological  treatment  is  designated  as  the  sole  option  for
improving  the  situation.  This  is  precisely  the  view  defended
by  the  ISSM’s  expert  group.  Should  we  consider  this  a  mere
coincidence?  Most  of  the  experts  are  aware  of  the  proﬁts  to
be  gained  by  the  pharmaceutical  industry.
However,  the  choice  to  relate  primary  PE  (characterised
by  ejaculation  latency  of  less  than  one  minute)  to  a  neurobi-
ological  dysfunction  is  based  on  a  syllogism.  Epidemiological
studies  cited  by  the  group  of  experts  indicate  that  many
bodily  diseases  (e.g.,  osteoporosis,  diabetes,  and  cardio-
vascular  diseases)  affect  approximately  0.5  to  2.5  %  of  the
population.  In  so  far  as  the  threshold  value  of  one  minute
of  penetration  reduces  the  proportion  of  men  concerned  to
about  the  same  number  (<  5  %,  see  above),  the  severe  form
of  PE  becomes  theoretically  equivalent  to  a  bodily  deﬁciency
(McMahon  et  al.,  2008).
This  syllogistic  logic  does  not  by  itself  prove  that  the
conclusion  is  wrong.  Evoking  other  arguments  to  support
their  proposal,  the  authors  cite  a  series  of  studies  that  point
to  the  contribution  of  bioconstitutional  factors  to  PE.  They
refer  to  Jern  et  al.  (2007), who  assessed  heritability  rates  of
PE,  all  types  combined,  at  28  %  in  a  series  of  Finnish  twins;
to  Corona  et  al.  (2011), who  suggested  a  potential  impact
of  the  hormonal  environment;  and  to  Janssen  et  al.  (2009),
who,  in  a  sample  of  PE  subjects  presenting  penetration  dura-
tions  of  less  than  one  minute,  noted  that  carriers  of  the  LL
variant  of  the  5-HTTLPR  gene  involved  in  serotonin  trans-
portation  were  characterised  by  even  shorter  ejaculation
latencies  than  counterpart  carriers  of  the  SS  and  SL  variants.
However,  nothing  in  these  studies,  or  in  any  other  studies
to  our  knowledge,  allows  concluding  that  these  biological
factors  play  an  exclusive  or  even  a  leading  role  in  primary
PE  with  ejaculation  latencies  of  less  than  one  minute.  The
reduction  of  this  clearly  severe  form  of  the  problem  to  a
neurochemical  imbalance  remains  completely  hypothetical
at  this  point.
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Consistent  with  the  perception  of  severe  primary  PE
attributable  to  a  bioconstitutional  deﬁciency,  the  long-term
use  of  serotonergic  agents  to  delay  the  ejaculation  reﬂex  has
often  been  presented  as  the  only  viable  treatment  (Althof
et  al.,  2010;  Porst,  2012;  Waldinger,  2007).  Yet  at  least
three  clinical  trials  appear  to  have  refuted  this  proposal.
Thus,  De  Carufel  and  Trudel  (2006),  De  Sutter  et  al.  (2002),
and  Kempeneers  et  al.  (2012)  found  that  subjects  affected
by  particularly  short  ejaculation  latency  may  also  respond
favourably  to  sexual  behavioural  therapy.  It  is  true  they
showed  less  improvement  in  comparison  to  PE  subjects  with
penetration  duration  exceeding  one  minute  (Kempeneers
et  al.,  2012),  but  there  were  improvements  nonetheless.
Similar  ﬁndings  were  obtained  for  medication  treatments
(Waldinger,  2007),  such  that  at  the  end  of  the  day,  latencies
shorter  than  one  minute  represent  a  severity  gradient  of  the
disorder  that  limits,  not  to  say  eradicates,  the  effectiveness
of  any  treatment  whatsoever.
By way of a conclusion
In  the  last  10  to  15  years,  many  studies  have  been  published
to  clarify  and  highlight  the  biological  tenets  of  PE.  Although
the  knowledge  has  been  advanced,  much  remains  to  be
explained  (Bonierbale,  2013).  In  the  wake  of  this  progress,  a
good  number  of  clinical  trials  of  pharmacological  treatments
for  this  problem  have  been  carried  out,  particularly  on  selec-
tive  serotonin  reuptake  inhibitors  (SSRIs).  In  comparison,
the  volume  of  publications  on  psychological  and  sociocul-
tural  aspects  is  insigniﬁcant,  with  clinical  trials  of  sexual
behavioural  approaches  accounting  for  barely  1000  subjects,
sometimes  contradictory  ﬁndings,  and  methods  that  are
uncertain  and  often  difﬁcult  to  compare  between  studies
(Berner  and  Gunzler,  2012;  Jern,  2013;  Kempeneers  et  al.,
in  press;  Melnik  et  al.,  2011).  This  disproportion  of  available
information,  which  has  arguably  been  commercially  inﬂu-
enced,  has  contributed  to  draw  public  and  clinical  attention
to  biological  and  chemotherapeutic  components  of  the  prob-
lem,  to  the  detriment  of  psychosocial  and  sex  therapy
components.  This  has  no  doubt  fostered  the  perception  that
PE  is  reduced  to  a  bodily  deﬁciency.
The  state  of  the  knowledge  does  not  allow  concluding
that  severe  forms  of  primary  PE  stem  from  a  neurobiologi-
cal  problem  that  can  be  treated  by  medications  alone.  While
fully  supporting  the  presence  of  bioconstitutional  factors
liable  to  increase  the  risk  for  PE  and  its  severity,  we  must  also
recognise  the  enormous  plasticity  of  the  biological  condi-
tion.  In  terms  of  penetration  time,  the  biological  norms  are
in  any  case  below  sociocultural  norms,  such  that  legions  of
‘biologically  normal’  men  must  learn  how  to  control  their
excitement  in  order  to  prolong  coitus  beyond  their  natu-
ral  limit.  And  many  manage  to  do  so,  with  or  without  the
help  of  a  sex  therapist.  The  logic  is  not  different  for  men
who  present  a  priori  penetration  times  of  less  than  one
minute.  It  could  be  more  difﬁcult  for  these  men  to  learn
new  behaviours,  but  not  impossible.
Two  therapeutic  strategies  are  available:  use  chemical
agents  to  act  on  nerve  transporters,  or  apply  behavioural
therapy  to  achieve  better  control  of  sexual  excitement.
It  appears  that  the  decision  to  use  either  of  these  strate-
gies  cannot  be  based  on  a  priori  penetration  duration.
In  addition,  they  can  be  viewed  as  fully  complementary
(Kempeneers  et  al.,  in  press).
Strictly  speaking,  due  to  the  potential  side  effects,  a
medication  strategy  should  not  be  proposed  as  the  ﬁrst-line
treatment,  and  probably  even  not  for  men  presenting  ejac-
ulatory  latency  times  of  less  than  one  minute.  In  time,  the
development  of  effective  self-treatment  instruments  should
make  sexual  therapy  more  accessible  as  a  ﬁrst-line  treat-
ment  (De  Sutter  et  al.,  2002;  Kempeneers  et  al.,  2012;
Kempeneers  et  al.,  in  press).  Moreover,  once  their  use  has
been  clariﬁed,  and  because  the  aim  is  to  relieve  suffer-
ing,  it would  be  unfortunate  if  medication  treatments  were
prohibited  when  psychosexological  treatment  proves  to  be
ineffective  or  impossible,  even  when  dealing  with  penetra-
tion  times  considered  statistically  normal.  Finally,  it  could
be  beneﬁcial  to  combine  the  two  treatment  types,  partic-
ularly  for  severe  forms  of  PE  that  are  resistant  to  either
approach  separately.  Although  their  synergistic  effects  have
been  established  (Li  et  al.,  2006;  Yuan  et  al.,  2008),  they
remain  underexplored.
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